Relief therapeutics « Terug naar discussie overzicht

Relief therapeutics Holding

9.097 Posts, Pagina: « 1 2 3 4 5 6 ... 450 451 452 453 454 455 | Laatste
Keeprolling
0
Forecast2006
1
quote:

Keeprolling schreef op 27 december 2022 18:53:

De koers is er per saldo niets mee opgeschoten. Terug naar de beginstand vandaag.
Komt goed, Amerika is positief op dit moment.

Kind regards,
Forecast
DeZwarteRidder
0
quote:

Keeprolling schreef op 27 december 2022 18:53:

De koers is er per saldo niets mee opgeschoten. Terug naar de beginstand vandaag.
De koers gaat onvermijdelijk verder zakken.

2 cent is al veel te duur.
DeZwarteRidder
0
Relief heeft ca 1 miljard aandelen klaarliggen om te dumpen, dus dit wordt weer huilen en janken.
€50_is_€50
0
Wat zijn hier de verwachtingen voor 2023?
Wordt het het jaar van de ommekeer met eindelijk een product op de markt van ACER en de beursgang op Nasdaq?
DeZwarteRidder
0
2023 wordt het jaar waarin vele miljarden nieuwe aandelen op de beurs worden gedumpt omdat Relief heel veel geld nodig heeft.
DeZwarteRidder
0
Pursuant to a Share Subscription Facility agreement (SSF),

GEM committed to provide up to CHF 50 million to RELIEF

THERAPEUTICS Holding SA in exchange for registered shares of

RELIEF THERAPEUTICS Holding SA in the period from

January 20, 2021, to January 20, 2024, at the discretion of

RELIEF THERAPEUTICS Holding SA, subject to certain

exceptions and limitations. No drawdowns have been made

until December 19, 2022,resulting in a remaining balance of

the full amount under the SSF of CHF 50 million. GEM's

purchase position has been calculated using the closing

price of the registered shares of RELIEF THERAPEUTICS

Holding SA on SIX Swiss Exchange on December 19, 2022 (CHF

0.0288) and applying the 10% discount agreed in the SSF

(resulting in a share price of CHF 0.02592), by dividing the

remaining balance under the SSF of CHF 50 million by such

share price of CHF 0.02592. However, according to the

terms of the SSF, future subscription prices under the SSF

will correspond to 90% of the average of the closing bid

prices on SIX Swiss Exchange during the relevant reference

period, which corresponds to 15 trading days following

RELIEF THERAPEUTICS Holding SA's relevant subscription

request, subject to certain exceptions and limitations.

Therefore, note that the actual subscription price at which

GEM may be requested to subscribe for registered shares

of RELIEF THERAPEUTICS Holding SA under the SSF may be lower

or higher than the share price applied above, and

accordingly, the number of voting rights GEM may acquire as

a result thereof may be higher or lower than as set

forth in this disclosure.
€50_is_€50
0
DeZwarteRidder
0
quote:

€50_is_€50 schreef op 2 januari 2023 13:34:

Mss moeten ze aviptadil maar in China op de markt brengen, ridder! ;-p
Dat is een heel goed idee......!!!

Aan een zieke Chinees kun je alles verkopen wat lijkt op een geneesmiddel.........
Forecast2006
0
laatsteloodje
0
quote:

DeZwarteRidder schreef op 2 januari 2023 13:42:

Aan een zieke Chinees kun je alles verkopen wat lijkt op een geneesmiddel.........
Dat is toch heel goed nieuws. Als 0,1% van de 1,4 miljard chinesen dit nutteloos middel kopen......
DeZwarteRidder
0
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
03.05.2023 / 07:00 CET/CEST

Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the implementation timeline for the reverse split of its ordinary shares, which was approved by shareholders at the Extraordinary General Meeting held on April 28, 2023.

May 4, 2023: Last trading day of old shares on SIX Swiss Exchange
May 5, 2023: First trading day of new shares on SIX Swiss Exchange

As previously communicated, shareholdings will be rounded down to the next lower whole number of new merged shares by applying the 400 to 1 exchange ratio. The resulting fractions will be compensated in cash at a fixed price corresponding to the three-day volume-weighted average price of the Relief Therapeutics share on the SIX Swiss Exchange prior to the reverse split.

Additional information on the reverse split is provided in a Q&A list available here.

ABOUT RELIEF THERAPEUTICS

Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief Therapeutics’ portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic™ and TEHCLO™ drug delivery platform technologies and a highly targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners. Our mission to provide therapeutic relief to those suffering from rare diseases is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief Therapeutics is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Rome. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, please visit our website www.relieftherapeutics.com or follow Relief Therapeutics on LinkedIn and Twitter
Ronduit
0
9.097 Posts, Pagina: « 1 2 3 4 5 6 ... 450 451 452 453 454 455 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 26 mei 2023 17:31
Koers 4,220
Verschil -0,580 (-12,08%)
Hoog 4,500
Laag 4,010
Volume 28.535
Volume gemiddeld 3.863.979
Volume gisteren 16.881

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront